Oxra 5 mg Tablet (Dapagliflozin)

Description

Introduction

Oxra 5 mg Tablet contains 5 mg of dapagliflozin. It is an oral medicine identified for the management of type 2 diabetes. Dapagliflozin helps lower blood glucose through an action in the kidneys. Its place in a treatment plan depends on a person’s medical history, kidney function and other medicines.

This description gives general information about the ingredient and the identified product. The prescription label and advice from a healthcare professional provide the directions for an individual’s treatment.

What Is It?

Oxra 5 mg is a tablet with dapagliflozin as its identified active ingredient. Dapagliflozin belongs to a class of medicines called sodium–glucose cotransporter 2, or SGLT2, inhibitors. Oxra is distinct from combination products that contain dapagliflozin together with another active ingredient.

Each tablet provides a 5 mg strength. The product is identified as a tablet, but its inactive ingredients and any coating should be checked on the supplied pack if an allergy or intolerance is a concern. A pharmacist can help interpret that information.

How Does It Work?

The kidneys filter glucose from the blood. A protein called SGLT2 normally helps return some of that glucose to the bloodstream. Dapagliflozin inhibits SGLT2, allowing more glucose to leave the body in urine. This can reduce blood glucose in people with type 2 diabetes.

The glucose-lowering effect depends partly on kidney function. Increased glucose in urine also draws water into urine, so some people may urinate more often or lose more fluid. These effects help explain several of the precautions associated with dapagliflozin.

Common Uses

Oxra 5 mg is identified for type 2 diabetes. Dapagliflozin may be used alongside diet and physical activity to improve blood glucose control. A prescriber may consider it alone or with other glucose-lowering medicines after reviewing the overall treatment plan.

Other dapagliflozin products have indications involving particular heart failure and chronic kidney disease populations. Those indications should not be assumed for Oxra 5 mg. Ask a healthcare professional for product-specific guidance if its intended use is unclear.

Available Strengths

This family is available in 5 mg, 10 mg.

Key Features

• Contains dapagliflozin as the identified active ingredient.
• Provides 5 mg of dapagliflozin per tablet.
• Is supplied as an oral tablet.
• Belongs to the SGLT2 inhibitor class of medicines.
• Is identified for the management of type 2 diabetes.

Benefits

• Dapagliflozin can improve blood glucose control in type 2 diabetes when used as part of an appropriate treatment plan.
• Its action in the kidneys differs from that of medicines that primarily increase insulin release.
• It may be considered with other glucose-lowering medicines when a prescriber finds the combination appropriate.
• When used without insulin or an insulin-releasing medicine, dapagliflozin has a lower risk of causing low blood glucose than those combinations.

The degree of blood glucose lowering varies between people and can be reduced when kidney function is impaired. Monitoring helps a healthcare professional assess the response.

Possible Side Effects

• Genital fungal infections, including thrush, can occur because dapagliflozin increases glucose in urine.
• Urinary tract infections may cause burning when passing urine, frequent urination or discomfort. Fever or back pain may indicate a more serious infection.
• Increased urination, thirst, dizziness or dehydration may occur, particularly during illness or other fluid loss.
• Low blood glucose is more likely when dapagliflozin is used with insulin or a medicine that increases insulin release.
• Ketoacidosis is an uncommon but serious problem. It can occur even when blood glucose is not very high.
• A rare, severe infection of the area around the genitals and anus needs urgent medical assessment.

This list does not include every possible adverse effect. New or concerning symptoms should be discussed with a healthcare professional.

Precautions

• Kidney function may need assessment before and during treatment because it affects dapagliflozin’s glucose-lowering action.
• A history of ketoacidosis, recurrent genital infections or urinary tract infections should be discussed with a prescriber.
• Conditions that cause vomiting, diarrhoea or reduced fluid intake can increase the risk of dehydration.
• Nausea, vomiting, abdominal pain, unusual tiredness or difficult breathing can be warning signs of ketoacidosis and need prompt assessment.
• Dapagliflozin is not a treatment for type 1 diabetes.

Additional Precautions

• Pregnancy or breastfeeding should be discussed with a healthcare professional before use.
• Illness, prolonged fasting and surgery can alter the risk of ketoacidosis. A prescriber can advise whether treatment needs to be interrupted.
• Older people and those taking medicines that increase urine output may be more vulnerable to dehydration or low blood pressure.
• Dapagliflozin causes glucose to appear in urine, which can affect the interpretation of urine glucose tests.
• Pain, swelling or redness around the genitals or perineum together with fever or feeling unwell requires urgent medical assessment.
• Signs of a serious allergic reaction, such as swelling of the face or difficulty breathing, require urgent care.

Storage Instructions

• Keep tablets in their original packaging and out of the reach of children.
• Follow the storage conditions printed on the supplied Oxra pack. Ask a pharmacist if the instructions are unclear.
• Do not use tablets after the expiry date shown on the pack.
• Ask a pharmacist how to dispose of unwanted or expired medicine.

How to Take

• Follow the directions on the prescription or dispensing label for this product.
• Swallow the tablet by mouth as directed by the prescriber.
• Ask a pharmacist if the administration instructions or a missed dose are unclear.
• Do not change the prescribed amount without advice from the prescriber.
• Attend recommended reviews of blood glucose and kidney function so the treatment response can be assessed.

Drug Interactions

• Insulin and insulin-releasing medicines, such as sulfonylureas, can increase the risk of low blood glucose when used with dapagliflozin.
• Diuretics can add to fluid loss and may increase the risk of dehydration or low blood pressure.
• Medicines that affect blood pressure, fluid balance or kidney function may require review as part of the overall treatment plan.
• Tell a healthcare professional about prescription medicines, non-prescription products and supplements before changes are made to treatment.

Why Choose This Product?

• Oxra 5 mg provides dapagliflozin in a clearly identified 5 mg tablet strength.
• Its identified active ingredient is dapagliflozin alone, which may matter when a treatment plan specifies a single-ingredient product.
• Dapagliflozin’s SGLT2 action and its blood glucose-lowering effect in type 2 diabetes are supported by clinical evidence.
• A healthcare professional can assess whether this ingredient and strength fit the intended treatment plan.

Frequently Asked Questions (FAQs)

What does Oxra 5 mg contain?

Each tablet contains 5 mg of dapagliflozin as its identified active ingredient.

Is Oxra 5 mg a combination tablet?

No. The identified product contains dapagliflozin as its active ingredient, without a second active medicine.

How does dapagliflozin lower blood glucose?

It reduces glucose reabsorption by the kidneys, allowing more glucose to leave in urine.

Is Oxra 5 mg used for type 1 diabetes?

No. It is identified for type 2 diabetes, and dapagliflozin is not a treatment for type 1 diabetes.

Can dapagliflozin cause low blood glucose?

Low blood glucose is more likely when it is combined with insulin or an insulin-releasing medicine.

Why might kidney function be checked?

Kidney function influences the glucose-lowering effect and helps inform treatment decisions.

What symptoms need urgent attention?

Symptoms suggesting ketoacidosis, a severe infection or a serious allergic reaction need urgent medical assessment.

Can it be used during pregnancy or breastfeeding?

A healthcare professional should assess this, as dapagliflozin may not be appropriate.

How should Oxra tablets be stored?

Follow the instructions on the supplied pack, keep it away from children and check the expiry date.

Related Products

• Oxra 5 mg Tablet (Dapagliflozin)
• Oxra 10 Mg Tablet (Dapagliflozin)
• Glimepiride 3 mg Australia
• Acarbose 25 mg Australia
• Voglibose 0.2 mg Australia
• Repaglinide 1 mg Australia